Enrollment completion with strong demand signals high investigator and patient interest, reducing clinical risk. Monitor for early 2027 data readout and any financing updates for the pivotal study. The rapid enrollment may accelerate timelines and increase partnership interest.
Price Chart
Executive Summary
Alpha Tau completed enrollment in its IMPACT pilot study of Alpha DaRT for pancreatic cancer, enrolling 48 patients (4x the original 12) after three expansions driven by strong demand. This de-risks the pancreatic program and supports the design of a planned pivotal study, with initial data expected in early 2027. The filing is a positive clinical milestone for a pre-commercialization company with a $1.4B market cap and strong analyst consensus.
Key Facts
- IMPACT study enrolled 48 patients, expanded three times from original 12-patient design
- Study conducted under U.S. IDE across 10 centers in US, Canada, and Israel
- Alpha DaRT delivered as one-time add-on to first-line chemotherapy (mFOLFIRINOX or gemcitabine + nab-paclitaxel)
- Initial data targeted for early 2027 to inform pivotal study design
- Global pancreatic program includes ACAPELLA trial in France and University of Verona study
- Pancreatic cancer is third leading cause of cancer death in US with ~66,000 new cases/year
Financial Impact
No financial data in filing; milestone de-risks pipeline for a pre-revenue company with $1.4B market cap
Risk Factors
- Pilot study only; no efficacy data yet — results may not support pivotal design
- Alpha DaRT not approved for any indication; regulatory path uncertain
- Company likely needs additional capital to fund pivotal study and operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-095370 |
| Document: ea0303693-6k_alpha.htm | 0001213900-26-095370 |
| Document: 0001213900-26-095370-index-headers.html | 0001213900-26-095370 |
| Document: 0001213900-26-095370-index.html | 0001213900-26-095370 |
| Document: 0001213900-26-095370.txt | 0001213900-26-095370 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access